MRC

MRC – Deadline: 28 Jun 2018

Biomedical Catalyst: Regenerative Medicine Research Committee

Supports translation of fundamental discoveries toward benefits to human health.

The translation of the burgeoning knowledge in regenerative medicine into new treatment strategies is a key objective of the MRC’s strategic plan. The Biomedical Catalyst: Regenerative Medicine Research Committee (RMRC) provides support for high quality proposals that may underpin or progress the development of  regenerative medicine therapies to improve human health. The RMRC:

  • Supports confidence in concept studies that if successful will promote the translation of fundamental discoveries toward benefits to human health, thereby accelerating the transition from discovery research to mature translational development projects
  • Funds preliminary work or feasibility studies to establish the viability of an approach, through addressing focussed research questions needed to unlock progress in pre-clinical development and/or early clinical testing of novel regenerative medicine therapies
  • Forms part of the MRC’s Translational Research Strategy and forms part of the Biomedical Catalyst funding stream, operating in conjunction with the Developmental Pathway Funding Scheme

For more information please visit the MRC website.

Advertisements

MRC – Deadline: 12 Jul 2018

Public Health Intervention Development Scheme (PHIND) 

The MRC Public Health Intervention Development scheme (PHIND) supports the early stages of development of interventions that address an important UK or global public health issue. Studies funded by the scheme will develop the necessary evidence to underpin the later development and evaluation of novel public health interventions.

The MRC PHIND scheme complements funding available from NIHRMRC Global Health and other sources for subsequent stages of public health intervention development and evaluation.

For more information please visit the MRC website.

MRC – Deadline: 25 Jul 2018

Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS)

The DPFS scheme is a key part of our Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.

Remit

The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.

Projects supported by the scheme have up to four clearly defined milestones, outcomes and future plans. These help to maximise both the chance of success and the likelihood of the project attracting the downstream funding, from public or private sources, required to meet its clinical and commercial aims. The funding panels assessing the project will, if necessary, help to develop proposals and suggest enhancements.

The following activities are eligible for support:

  • Developing candidate therapeutic entities (e.g. drug discovery)
  • Pre-clinical testing of novel therapeutic entities
  • Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)
  • “Repurposing” clinical studies – using existing therapies for new indications
  • Developing and testing novel devices
  • Developing and testing diagnostics (including biomarker validation)

Individual projects can start and finish at any point along the translational pathway but would not typically progress from initial development through to phase 2 clinical testing in a single application. Where there is a justified need for continued MRC support, sequential applications are encouraged.

All disease areas (including those relevant to global health) and modalities of intervention are eligible for support from the scheme, including small molecules, peptides, antibodies, vaccines, cell and gene therapy, devices, surgical techniques and psychological approaches.

 

For more information please visit the MRC website.

MRC Harwell: Deadline 27 Jul 2018

Genome editing mice for medicine grant

The Harwell international centre for mouse genetics, under the Medical Research Council, invites nominations for its . This supports the production of genetically modified mouse lines that advance knowledge of human disease or are of widespread use in biomedical science. Nominations should consider specific genetic alterations in the mouse using genome editing technologies. They will be assessed by the nominator’s own research hypotheses and plans for utilising the mouse as well as by the impact the proposed novel mouse line will have on the academic community. In addition to single mouse lines, nominations for collections or groups of lines within specific theme or discipline will be considered. The following allele types or methodologies are available: indels, deletions, point mutation insertions, cassette knock-ins and conditional or Tm1a allele generation.

Researchers and groups based in UK higher education institutes, independent research organisations, government-funded organisations, university units and MRC units and institutes may nominate. They must have necessary interests, expertise, licences and facilities to work with animals and carry out the research. Collaborations and team approaches are encouraged.

The total budget is worth £4.5 million over five years. The award covers mouse line generation and archiving but not other research costs. For more information visit the GEMM website.

MRC – Deadline: 5 Sep 2018

New Investigator Research Grant – Molecular & Cellular Medicine – Research boards

The New Investigator Research Grant (NIRG) is aimed at researchers who are capable of becoming independent Principal Investigators and who are now ready to take the next step towards that goal. You can apply across all areas of the MRC’s remit.

For more information please visit the MRC website.

MRC – Deadline: 5 Sep 2018

Programme grants – Molecular & Cellular Medicine – Research boards

Suitable for focused research projects. Grants are usually worth up to £1 million on the basis of 80 per cent of full economic costs of the research, for a maximum period of five years.

More information about this call can be found at the MRC website.

 

MRC – Deadline 6 Sep 2018

Clinical Research Training Fellowship (CRTF) pre-doctoral

The CRTF supports clinicians, including (but not limited to) medics, surgeons, dentists, clinical psychologists, public health specialty trainees, allied health professionals, nurses, midwives and veterinarians, to undertake a PhD or other higher research degree.

Clinical Research Training Fellowship (CRTF) post-doctoral

The scheme also provides a route for post-doctoral applicants who achieved their PhD some time ago but who have not been research active since due to clinical training commitments to reacquire research skills.

For more information please visit the MRC website.

MRC/ GACD/ NIHR – Deadline: 10 Sep 2018

GACD: scaling-up > hypertension and/or diabetes

The MRC and the National Institute for Health Research (NIHR), in partnership with the Global Alliance for Chronic Diseases (GACD) is seeking to generate new knowledge on interventions and their implementation for the prevention or management of hypertension and/or diabetes.

The call will support research associated with the scale-up of interventions for the prevention, and/or detection and management of hypertension and/or diabetes in low and middle-income countries (LMICs). Collectively, the MRC and NIHR will invest up to £6 million for this initiative. This amount is expected to fund several awards.

The following principles should be reflected in this call:

•commitment to improving health gains while reducing health disparities in LMICs;

•focus on research topics where the need for evidence to inform policy, programmes and practice is most urgent;

•pursuit of knowledge translation and exchange approaches that are designed to maximise the public health benefits of research findings;

•identification of common approaches for implementation, integration and scale up within different health systems.

For more information please visit the MRC website or the GACD website.

MRC – Deadline: 19 Sep 2018

New Investigator Research Grant – Infections and Immunity (IIB) – Research Boards

The New Investigator Research Grant (NIRG) is aimed at researchers who are capable of becoming independent Principal Investigators and who are now ready to take the next step towards that goal. You can apply across all areas of the MRC’s remit.
For more information please visit the MRC website